Aims and objectives of this presentation
Prostate MRI is gaining more importance in diagnosis of prostate cancer but the exact indication is still unclear. This session will highlight new data on the indication for an MRI before the first and second biopsy and in active surveillance patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

*497
Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam
By: Alberts A.\(^1\), Roobol M.\(^1\), Bokhorst L.\(^1\), Drost F.-J.\(^2\), Van Leenders G.\(^3\), Dwarkasing R.\(^2\), Barentsz J.\(^4\), Schröder F.\(^1\), Bangma C.\(^3\), Schoots I.\(^1\)
Institutes: Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, \(^2\)Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, \(^3\)Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, \(^4\)Radboudumc, Dept. of Radiology, Nijmegen, The Netherlands

*498
The UCL PICTURE trial: A prospective cohort validating study evaluating the accuracy of multi-parametric MRI and prostate HistoScanning compared to transperineal template mapping biopsies in patients requiring risk stratification after prior transrectal prostate biopsy
By: Simmons L.\(^1\), Kanthabalan A.\(^1\), Hu Y.\(^2\), Barrat D.\(^3\), Punwani S.\(^3\), Ramachandran N.\(^3\), Jameson C.\(^3\), Freeman A.\(^4\), McCartan N.\(^1\), Briggs T.\(^5\), Gelister J.\(^6\), Charman S.\(^6\), Van Der Muelen J.\(^6\), Moore C.\(^1\), Ahmed H.\(^1\), Emberton M.\(^1\)
Institutes: \(^1\)University College Hospitals London, Dept. of Surgery and Interventional Science, London, United Kingdom, \(^2\)University College London, Centre For Medical Imaging and Computing, London, United Kingdom, \(^3\)University College Hospitals London, Dept. of Radiology, London, United Kingdom, \(^4\)University College Hospital London, Dept. of Pathology, London, United Kingdom, \(^5\)Barnet Hospital, The Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, \(^6\)London School of Hygiene and Tropical Medicine, Dept. of Health Services Research and Policy, London, United Kingdom

*499
A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Preliminary results
By: Porpiglia F.\(^1\), Mele F.\(^1\), Manfredi M.\(^1\), Aimar R.\(^1\), Checcucci E.\(^1\), Cosso M.\(^1\), Pollito E.\(^2\), Russo F.\(^3\), Gned D.\(^4\), De Pascale A.\(^4\), Cirillo S.\(^5\), Fiori C.\(^1\)
Institutes: \(^1\)San Luigi Gonzaga Hospital, Dept. of Urology, University of Turin, Orbassano, Turin, Italy, \(^2\)San Luigi Gonzaga Hospital, Dept. of Pathology, University of Turin, Orbassano, Turin, Italy, \(^3\)Candiolo Cancer Institute, Division of Radiology, Candiolo, Turin, Italy, \(^4\)San Luigi Gonzaga Hospital, Division of Radiology, University of Turin, Orbassano, Turin, Italy, \(^5\)Mauriziano Hospital, Division of Radiology, Turin, Italy

*500
Multiparametric magnetic resonance imaging and MRI/TRUS-fusion–biopsy for index tumor detection: Correlation with radical prostatectomy specimen
By: Radtke J.P.\(^1\), Schwab C.\(^1\), Wolf M.\(^2\), Freitag M.\(^2\), Alt C.\(^2\), Kesch C.\(^1\), Popencuc I.V.\(^1\), Huettenbrink
Is a negative mpMRI really able to rule out significant prostate cancer?
By: Branger N.1, Maubon T.1, Traumann M.1, Thomassin J.2, Pacienza M.2, Brunelle S.2, Salem N.4, Gravis G.3, Walz J.1
Institutes: 1Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, 2Institut Paoli-Calmettes, Dept. of Pathology, Marseille, France, 3Institut Paoli-Calmettes, Dept. of Radiology, Marseille, France, 4Institut Paoli-Calmettes, Dept. of Radiotherapy, Marseille, France

Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy
By: Kesch C.1, Radtke J.P.1, Roth W.2, Roethke M.3, Schlemmer H.P.3, Hohenfellner M.1, Hadaschik B.1
Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany, 3German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany

Evaluation of PI-RADS classification in prediction of tumor-aggressiveness in targeted biopsy
By: Borkowetz A.1, Platzek I.2, Toma M.3, Renner T.1, Fröhner M.3, Koch R.4, Zastrowitz S.1, Wirth M.1
Institutes: 1University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, 2University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, 3University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany, 4University Hospital, TU Dresden, Institute For Medical Informatics and Biometry, Dresden, Germany

Poor reproducibility of PI-RADS score in 2 multiparametric MRIs before biopsy in men with elevated PSA
By: Müller S., Løfsgaard L., Estop-Garanto M., Sand T.E., Helgø D., Sund P., Mygland V.
Institutes: Akershus University Hospital, Dept. of Urology, Lørenskog, Norway

Targeted PET/TRUS software fusion-guided biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy: A feasibility study and preliminary results
By: Lopci E.2, Lazzari M.1, Lughezzani G.1, Pasini L.1, Hurle R.1, Leonardo L.2, Casale P.1, Buffi N.1, Peschecchia R.1, Rodari M.2, Zandegiacomo S.1, Benetti A.1, Fiorini G.1, Chiti A.2, Guazzoni G.4
Institutes: 1Istituto Clinico Humanitas IRCCS, Dept. of Urology, Milan, Italy, 2Istituto Clinico Humanitas IRCCS, Dept. of Nuclear Medicine, Milan, Italy, 3Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Nuclear Medicine, Milan, Italy, 4Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Urology, Milan, Italy

MRI guided prostate biopsy: What is the place of PCA3 score?
By: Roumiguie M.1, Beauval J.B.1, Nogueira L.2, Portalez D.3, Soulie M.1, Rischmann P.1, Malavaud B.1
Institutes: 1CHU Rangueil, Dept. of Urology, Toulouse, France, 2CHU Purpan, Dept. of Biology, Toulouse, France, 3CHU Rangueil, Dept. of Radiology, Toulouse, France

Low apparent diffusion coefficient (ADC) value is associated with biochemical recurrence in high risk prostate cancer patients
Institutes: Seoul National University Hospital, Dept. of Urology, Seoul, South Korea

Summary and context
B.A. Hadaschik, Heidelberg (DE)